The Ras homolog enriched in striatum, Rhes, is the product of a thyroid hormone-regulated gene during brain development. Rhes and the dexamethasone-induced Dexras1 define a novel distinct subfamily of proteins within the Ras family, characterized by an extended variable domain in the carboxyl terminal region. We have carried this study because there is a complete lack of knowledge on Rhes signaling. We show that in PC12 cells, Rhes is targeted to the plasma membrane by farnesylation. We demonstrate that about 30% of the native Rhes protein is bound to GTP and this proportion is unaltered by typical Ras family nucleotide exchange factors. However, Rhes is not transforming in murine fibroblasts. We have also examined the role of Rhes in cell signaling. Rhes does not stimulate the ERK pathway. By contrast, it binds to and activates PI3K. On the other hand, we demonstrate that Rhes impairs the activation of the cAMP/PKA pathway by thyroid-stimulating hormone, and by an activated b2 adrenergic receptor by a mechanism that suggests uncoupling of the receptor to its cognate heterotrimeric complex. Overall, our results provide the initial insights into the role in signal transduction of this novel Ras family member.
Introduction
The Ras family of small GTPases comprises several protein subfamilies (for recent reviews, see Campbell et al., 1998; Reuther and Der, 2000) . Among the most recent additions made to the Ras superfamily are two proteins whose expression is regulated by hormones, Dexras1 and Rhes: Dexras1 was originally found in mice, and its name reflects the fact that it was induced by dexamethasone (Kemppainen and Behrend, 1998) . A human Dexras homologue was subsequently isolated in a functional screen in yeast designed to identify receptor-independent activators of heterotrimeric G protein signaling, and was named as AGS1 (Cismowski et al., 1999 (Cismowski et al., , 2000 . AGS1 was proposed to function as a guanine nucleotide exchange factor for Gai/Ga0. Dexras1/AGS1 was subsequently found to inhibit receptormediated Gai signalling by interfering with receptor-Gai coupling (Graham et al., 2002; Takesono et al., 2002) . In other studies, Dexras1 was found to be cytoplasmic and was activated by S-nitrosylation induced by nNOS in response to NMDA receptor activation in brain (Fang et al., 2000; Jaffrey et al., 2002) .
We have described another Ras family member, which we named Rhes because it is greatly enriched in the striatum (Falk et al., 1999) . A human Rhes ortholog was identified as a tumour endothelial marker and was named TEM-2 (St Croix et al., 2000) . Rhes shares 62% identity with Dexras1 and is upregulated by thyroid hormone during the postnatal period in the rat (Vargiu et al., 2001) . Both proteins contain domains present in prototypical Ras proteins including GTP binding and effector domains, a CAAX box for membrane localization, and an extended C-terminal variable domain that accounts for their greater molecular mass.
However, the specific involvement of Rhes in signalling pathways has not been analysed thus far. Herein we present evidence indicating that, under basal conditions, a high proportion of wild-type Rhes exists in the GTPbound form, but it displays no transforming activity. With regards to effector usage, Rhes does not activate the ERK pathway but is capable of binding to, and activate PI3K. Interestingly, we also found that Rhes inhibited the activation of a cAMP responsive element induced by a constitutively active b2-adrenergic receptor, but not when induced by forskolin or by a constitutively active Gas protein. Overall, our results indicate that Rhes displays distinctive characteristics among Ras GTPases, in particular in its role in the coupling between serpentine membrane receptors and heterotrimeric G protein signaling.
Results

The Rhes/Dexras subfamily
On the basis of sequence homology and gene tree calculations, Rhes and Dexras1 define a distinct subfamily of proteins within the Ras family ( Figure 1 ). Rhes has also been named as Dexras2, but we think that the term is not appropriate because Rhes is not induced by dexamethasone (Falk et al., 1999) . Also, as shown in this work, there are a number of differences regarding intracellular signaling. Species distribution of Dexras/ Rhes proteins suggests an early origin in the evolution of this new family, at least previous to the chordate divergence. Longer branch lengths of the gene tree observed in Rhes and Dexras sequences point to a more accelerated rate of amino-acid replacement and may reflect reduced functional constrains or adaptation to novel functions. The gene tree also shows that Dexras and Rhes sequences appeared in mammals after their separation from insects. Distinguishing features of Dexras/Rhes proteins (Falk et al., 1999) include an extended carboxyl terminus variable domain of about 56 amino acids in Rhes (residues 210-266) and 70 amino acids in Dexras1 (residues 210-280), and an inserted region of eight amino acids preceding the G2 motif. It is possible that this additional region, shared by Rhes and Dexras proteins, could carry out a specific function in these sequences and it might mediate specific interactions with other proteins (Wittinghofer and Valencia, 1995) . These characteristics prompted us to undertake an analysis of Rhes biochemical properties in further detail.
Rhes expression
Rhes was originally identified as a cDNA clone encoding an mRNA very enriched in the striatum. As mentioned above, its gene product exhibits remarkable characteristics. Thus, it was of interest to identify neural pathways that might be influenced by Rhes.
For this purpose, a notion about the areas in the brain where Rhes was expressed could provide valuable clues. Thus, we performed in situ hybridization in saggital and coronal slices of adult rat brain using a radioactively labelled Rhes riboprobe. In Figure 2 panel a, representative images from saggital and coronal sections from adult rat brain are displayed. Rhes was prominently expressed in the striatum, but it was not restricted to this region and was also detected in other areas, such as the mitral cell layer of the olfactory bulb, olfactory tubercle, piriform cortex, layers 2/3 and 5 of cerebral cortex, accumbens nucleus, subiculum, pyramidal and granular layers of the hippocampus, anterior thalamic nuclei, inferior colliculus, and granular layer of the cerebellum. Interestingly, and although Rhes appeared to be primarily expressed in the brain among other organs, an mRNA of the expected size was also detected in the thyroid gland ( Figure 2 , panel c).
To gain an insight into what types of cells express Rhes, we analysed its expression among a panel of neural cell lines. Rhes mRNA could be detected in undifferentiated PC12 cells (Figure 2 , panel b). However, no Rhes transcripts were detected in other neuronal cells such as GT1-7 (Mellon et al., 1990) , or N2a cells, neither under basal conditions nor upon stimulation with thyroid hormones. Rhes mRNA was also undetected in the C6 glial cell line in agreement with its neuronal expression in vivo (Vargiu et al., 2001) . In PC12 cells, Rhes expression was not altered by T3 treatment or after the induction of differentiation by NGF (not shown).
Subcellular localization
We then investigated Rhes subcellular localization. This was undertaken in a physiological environment such as PC12 cells. The presence of a conserved CAAX box in the Rhes carboxyl terminus (CSIQ in rat Rhes and CTIQ in human Rhes) predicts targeting of the protein to the plasma membrane. Thus, to examine Rhes localization to the plasma membrane, PC12 cells were transfected with vectors encoding Rhes fused to the carboxyl terminus of the green fluorescent protein. As shown in Figure 3 , panel c, confocal microscopy revealed that the GFP--Rhes fusion protein was clearly present in the plasma membrane. This was confirmed by indirect immunofluorescence utilizing anti-AU5 antibodies, after transfection of PC12 cells with AU5-tagged Rhes (Figure 3, panel a) . Conversely, a GFP--Rhes construct harbouring a Cys to Ala mutation within the CAAX box (Rhes C263A) was soluble and could not be located in the plasma membrane (Figure 3 , panel g). We then used specific inhibitors of farnesylation or of geranylgeranylation to check for the nature of the lipid moiety attached to the Rhes C-terminus. Therefore, it may be concluded that Rhes undergoes post-translational farnesylation and is targeted to the membrane.
GTP binding and transforming activity
The Rhes sequence shows the presence of serine and arginine residues in positions 28 and 29, equivalent to Ras glycines 12 and 13. In Ras, mutations in these positions suppress its GTPase activity and render a constitutively active, transforming protein. Therefore, we checked whether this was the case for Rhes. First, we determined to which guanosine nucleotide Rhes was preferentially bound under unstimulated conditions. PC12 cells were transfected with expression plasmids encoding AU5-tagged Rhes or H-Ras, and nucleotide binding was analysed in anti AU5 immunoprecipitates from serum-starved cells after incubation with 32 P-orthophosphate in phosphate-free medium. Data from different experiments, shown in Figure 4 , were pooled and analysed by ANOVA (result: F 10,26 ¼ 15.497; P ¼ 0.000). About 18% of H-Ras was found in the GTP-bound form. Interestingly, Rhes contained as much as 30% in the GTP form, suggesting that wildtype Rhes could be constitutively activated (Po0.05, as compared to H-Ras). We also tested whether GEFs specific for the Ras family could catalyse GDP/GTP Rhes inhibits GPCR signalling P Vargiu et al exchange on Rhes. As expected, it was found that the proportion of bound GTP in H-Ras increased to 30 and 35% in the presence of SOS and CalDAG3, respectively (Po0.05). The Rap-specific GEFs CALDAG1 or C3G were ineffective for catalysing GDP/GTP exchange on H-Ras (nonsignificant differences versus H-Ras in the absence of GEFs). Interestingly, none of the tested GEFs were capable of eliciting a statistically significant change in the proportion of GTP bound to Rhes. In light of these data, we proceeded to determine whether Rhes could induce cellular transformation in murine NIH3T3 fibroblasts. Focus forming assays were performed using wild-type Rhes and the N77L mutant of Rhes (equivalent to the Q61L-activating mutation in H-Ras), and as a positive control H-Ras V12. Figure 5 shows that in contrast to the RasV12 (4274 foci), the number of foci produced with wild-type Rhes (872) or with the N77L mutant (672) was similar to that obtained with the vector alone (972).
Rhes displays low affinity for Raf and does not activate the ERK pathway
Our next goal was to analyse whether Rhes could activate the typical Ras effector pathways. We first analysed whether Rhes was capable of binding to Raf and thereby, regulating the activation of the ERK pathway. To this end, we performed an in vitro binding assay using a bacterially expressed GST-fusion protein of the Raf1 Ras-binding domain (RBD). For the binding assays, we used protein extracts from transfected HeLa cells expressing AU5-tagged vectors encoding Rhes, H-RasV12 as a positive control, and Rac1 as negative control. After GST pull-down and immunoblotting with anti AU5, we found that RasV12, but not Rac1, displayed Raf1 binding as expected, (Figure 6 , panel a). In comparison to RasV12, Raf-RBD could only retrieve a very faint band of Rhes, suggestive of low binding affinity and, therefore, that Raf1 was not a likely Rhes effector. Direct examination of ERK activation confirmed this conclusion. Cos-7 cells were cotransfected with a hemagglutinin (HA)-tagged Erk2 together with Rhes, RasV12 as a positive control, H-Ras wild type, or the empty vector. ERK activity was subsequently assayed in anti-HA immunoprecipitates, using MBP as a substrate. In cells transfected with Rhes, there was no increased MBP phosphorylation above the level observed with the plasmid alone ( Figure 6, panel b) .
Rhes binds to and activates phosphoinositide 3-kinase
We also determined whether Rhes was involved in the regulation of the PI3K pathway. To do so, we used the same methodology as above and we checked for Rhes binding to the RBD of the PI3K catalytic subunit (p110a) fused to GST. Extracts from cells transfected with AU5-tagged Rhes, Ras V12, or RhoA as a negative control were incubated with the GST fusion protein, and the PI3K RBD-bound proteins were resolved by immunoblotting. The results presented in Figure 6 panel a show that, as expected, Rho A did not bind PI3K, whereas a clear binding was obtained for Rhes as well as for Ras V12. To evaluate the effect of Rhes in PI3K activity, we measured the activity of the PI3K target Akt/PKB (Datta et al., 1996) by transiently expressing an HA-tagged Akt and measuring phosphorylation of histone H2B as substrate. Cotransfection with a Rhes is not transforming in murine fibroblasts. NIH 3T3 cells were transfected with 0.1 mg of RasV12 as a positive control, 0.5 mg of wild-type Rhes, 0.5 mg Rhes N77L, or 0.5 mg of pCEFL plasmid. The number of foci was counted after 2 weeks of transfection Rhes inhibits GPCR signalling P Vargiu et al constitutively active form of PI3K resulted in phosphorylation of the substrate. Likewise, cotransfected Rhes was also able to induce Akt-mediated phosphotransfer onto histone H2B ( Figure 6 , panel b), thereby indicating that Rhes was capable of activating the PI3K/Akt signalling route. In contrast to wild-type Rhes, the C263A Rhes mutant had no effect, demonstrating that for stimulation of PI3K Rhes had to be targeted to the membrane.
A role of Rhes in G protein-coupled receptor signaling
Recent evidence implicates the Rhes homolog Dexras1 in the activation of Gai proteins (Cismowski et al., 2000) . Indeed, a Dexras cDNA clone was isolated in a screen designed to identify proteins promoting the emission of signals by heterotrimeric G proteins. We checked whether Rhes, as Dexras1, had any effect on signalling transduction from receptors coupled to Gi proteins. To this end, we used the M 2 muscarinic receptor (M 2 -MR). PC12 cells were stimulated with carbachol in the absence or presence of transfected M 2 -MR and/or Rhes. As an end point, we measured the activity of a chloramphenicol acetyl-transferase (CAT)
reporter gene containing the serum response element (SRE). The result is shown in Figure 7 . Activation of the SRE in the reporter took place similarly in the presence or absence of Rhes, making it unlikely that Rhes influences signalling through Gi proteins. We then explored the possibility that Rhes may influence signalling through Gs proteins. Since Rhes is expressed in the thyroid gland, we performed a similar experiment using the human TSH receptor as a Gscoupled receptor. As an end point, we measured the activity of a CAT reporter construct containing a tandem repeat of four CRE sites after stimulation with bovine TSH. The result is shown in Figure 8 , panel a. Increasing the concentrations of TSH in the medium led to a progressive increase of reporter activity, up to five times the basal activity in the absence of the hormone. In the presence of Rhes, TSH also increased reporter activity, but the effect was about half of those achieved in the absence of Rhes. The results of these experiments therefore indicate that Rhes inhibited signal transduction from a Gs protein coupled to cAMP production.
To obtain initial data on the site of action of Rhes within the signal transduction pathway leading to cAMP production and stimulation of the CRE, we Rhes inhibits GPCR signalling P Vargiu et al evaluated the effect of Rhes on the stimulation of the cAMP pathway by different activators acting at different levels of the pathway. For this task, we used a constitutively acting mutant of the b 2 -adrenergic receptor (Samama et al., 1993) , the activated Gas QL (Landis et al., 1989) or direct stimulation of PKA with forskolin. The effects of these activators were monitored by measuring the activity of a CAT reporter gene under the control of a tandem repeat of four CREs. As shown in Figure 8 panel b, expression of the constitutively active b2-adrenergic receptor led to a marked increase activity of the CRE-CAT reporter gene. Interestingly, cotransfection with increasing amounts of Rhes led to a dose-dependent inhibition of the receptor-induced reporter activity. This inhibitory effect of Rhes required targeting to the cell membrane, since Rhes C263A impaired for binding to the membrane did not affect the b-adrenergic receptor effect. In an independent experiment, we compared the effect of Rhes on the b2-adrenergic receptor with that on a constitutively acting Gas protein, and with forskolin ( Figure 8, panel  c) . Expression of GasQL, or addition of forskolin, led to a highly increased activity of the reporter. Again, wildtype Rhes, but not Rhes C263A, inhibited the activation induced by the b2-adrenergic receptor. However, Rhes had no effect on the activation of the CRE-responsive reporter induced by the activated mutant GasQL or by the addition of forskolin. These experiments indicate therefore that Rhes regulates the activation of the cAMP/PKA pathway upstream of the activation of the heterotrimeric G protein complex.
Discussion
In this study, we have provided a first insight into Rhes biochemical properties. Rhes was initially discovered as an mRNA greatly enriched in the striatum. Rhes is one of the targets of thyroid hormone during the neonatal Figure 7 Rhes has no effects on stimulation of the muscarinic receptor by carbachol. PC12 cells were transfected with expression plasmids encoding the M2-MR with or without Rhes, and the stimulation of a CAT reporter plasmid harbouring a serum response element was measured in response to carbachol Figure 8 (a) Rhes inhibits signalling by the TSH receptor. PC12 cells were transfected with expression plasmids encoding the human TSH receptor with or without Rhes, and the stimulation of a CAT reporter plasmid harbouring four tandem copies of the cAMP response element was measured in response to different concentrations of bovine TSH. (b) Rhes expression inhibits the activation of a CRE in response to b2-adrenergic receptor stimulation. Cells were cotransfected with plasmids encoding a constitutively active receptor and a CAT reporter gene under control of a tandem repeat of four CRE (4 Â CRE) sites, with or without increasing amounts of wild-type Rhes, or Rhes harbouring a mutation in the CAAX box that prevents membrane targeting (RhesC263A). (c) Rhes has no effect on the stimulation of the CRE-CAT reporter gene induced by the activated GasQL protein or by forskolin Rhes inhibits GPCR signalling P Vargiu et al period, the critical time for thyroid hormone-dependent brain maturation. In addition to the striatum, Rhes is also expressed in other areas of the brain, such as the cerebral cortex, hippocampus, inferior colliculus, and cerebellum. Expression of Dexras1 also occurs mainly in the brain, with low levels of expression in other tissues (Fang et al., 2000) . The distribution of Dexras1 in brain has not been reported in detail, but the available data indicate that it is different from Rhes. In addition to predominant expression in the striatum, Rhes is also expressed in the granular cells of the cerebellum, whereas Dexras1 is expressed in the Purkinje cells. Expression in the striatum and the cerebellum suggests that Rhes is involved in pathways related to neuromotor control, which would be in agreement with the striatopallidal syndrome typical of neurological cretinism (Delong et al., 1985) . It is interesting that, among the organs analysed, Rhes was only found in the thyroid gland, suggesting a role in the modulation of thyroid hormone secretion. This idea is further supported by our finding that Rhes modulates the action of TSH through its receptor. Of considerable interest is the recent report (Chan et al., 2002) that Rhes is also expressed in the pancreas where it may control insulin secretion and be a target of imidazolin secretagogues. Dexras1 is predominantly cytoplasmic (Fang et al., 2000) ; this is in sharp contrast to Rhes. Rhes sequence presents a conserved CAAX box, CSIQ in rat Rhes and CTIQ in human Rhes. A similar C-terminal sequence is present in human Rap2 (CNIQ), which undergoes farnesylation (Farrell et al., 1993) . Likewise, our results clearly indicate that Rhes is farnesylated and targeted to the plasma membrane via this post-translational modification.
Interestingly our results indicate that, when compared to H-Ras, wild-type Rhes contained a high proportion of bound nucleotide in the form of GTP under unstimulated conditions. It is known that single amino-acid substitutions within Ras residues 116-119, a region that interacts with the guanine ring, result in a constitutive activation as a result of reduced nucleotide affinity, resulting in GEF-independent nucleotide exchange (Clanton et al., 1986; Walter et al., 1986) . It is noteworthy that Rhes maintains the consensus sequence N-K-X-D (NKND in Rhes) within this region. Thus, a reduced affinity for binding to the guanine ring should not account for the high levels of GTP-bound Rhes. Alternatively, this phenomenon could be explained by a reduced intrinsic GTPase activity. This may find a precedent in RhoE, a constitutively active protein that displays no GTPase activity and contains all of nucleotide bound in the form of GTP (Foster et al., 1996) . This property of RhoE is due to amino-acid substitutions in positions corresponding to H-Ras 12, 59, and 61. Most notably, the corresponding positions of Rhes and Dexras proteins show similar amino-acid substitutions, that is, a serine residue is present in positions corresponding to residues 12 and 59 of H-Ras, although residue 61 is conservatively replaced by asparagine. These and other amino-acid substitutions in the corresponding positions 13 (arginine instead of glycine) and 63 (proline instead of glutamic acid) of H-Ras, which are also important for GTPase activity, predict that Rhes intrinsic GTPase activity is low.
Recent reports suggest that Dexras1 is activated by nNOS-induced S-nitrosylation in Cys 11 (Jaffrey et al., 2002) , a reaction facilitated by Dexras1 binding to the adaptor protein CAPON. Interestingly, H-Ras can be induced to undergo nucleotide exchange by NO, through a GEF-independent mechanism that involves the destabilization of the interaction between residues in the GDP-binding pocket and the nucleotide, rather than the NO-induced modification of cysteine 118 (Mott et al., 1997) . Whether Rhes is also subject to S-nitrosylation is not known, but it is possible that Rhes and Dexras1 are subject to the same type of regulation by nitrogen metabolites. Such a regulatory mechanism may also help to explain the high proportion of Rhes bound to GTP under what we consider basal conditions in our experimental setting. Furthermore, our results demonstrate that Rhes is insensitive to Rasand Rap-specific GEFs. Although at this stage we cannot rule out that others as yet unidentified GEFs catalyse Rhes GDP/GTP transit, a GEF-independent activation such as the one proposed is an attractive alternative. In addition, how Rhes responds to GAP proteins GTPase-potentiating activity is another potential level of regulation that has not been explored thus far, which may shed some light into its regulation.
The multiple sequence alignment of Rhes and Dexras sequences (Graham et al., 2001) shows the conservation of all GTP-binding motives of Ras-like proteins. They also share conserved important residues in the effector regions compared with the Ras subfamily, like Isoleucine 52 in rat Rhes (Ile 36 in Human H-Ras) and the glutamic acid residue in position 53 (37 in human H-Ras). These last residues are known to be critical for RBD-specific recognition by Ras proteins (Bauer et al., 1999) . However, it is important to note that within its effector domain Rhes exhibits an important substitution in Thr 49 corresponding to Asp 33 in H-Ras. This position is very important in the Ras family for the interaction with Raf (Chuang et al., 1994) . This agrees with our findings demonstrating that Rhes had low affinity for Raf1 and did not activate the ERK pathway. By contrast, Rhes was able to associate with and activate PI3K, an interaction which is unaffected by the substitution at position 49.
Finally, we have observed that Rhes has a remarkable role in GPCR signalling. Rhes interfered with stimulation of the cAMP/PKA pathway mediated by the TSH receptor and by a constitutively active form of the b2-adrenergic receptor. In contrast, it was without effect on a constitutively active Gas or to the direct activation of PKA. These results strongly suggest that Rhes is acting somewhere upstream of the activation of the heterotrimeric complex by the receptor. This would be in agreement with data from Cismowski et al. (1999 Cismowski et al. ( , 2000 , Takesono et al. (2002) , and Graham et al. (2002) in which a Ras family protein would directly modulate the activation of a heterotrimeric G protein. The mechanism is not clear. Concerning Dexras1/AGS1, it has been proposed that this protein alters the pool of G protein available for receptor interaction, thereby uncoupling the receptor from its effector (Graham et al., 2002) . In our case, we contemplate three hypotheses. (1) Rhes competes with Gas for binding to the receptor, and therefore an overexpression of Rhes would uncouple the receptor from the heterotrimeric complex and preclude its activation. (2) Rhes heterodimerizes with Gas when GDP-bound precluding it from loading with GTP. Rhes would not affect signalling by Gas QL as it is bound to GTP constitutively and would not be able to interact with it. (3) The inhibitory effect would not be directly mediated by Rhes, but by a hitherto unidentified kinase activated by the GTPase that would phosphorylate and thereby uncouple the b2-adrenergic receptor from the heterotrimeric complex. Uncoupling by phosphorylation is a common mechanism and has been previously demonstrated in the case of the b2-adrenergic receptor (Daaka et al., 1997) . These three possibilities warrant further investigation.
Materials and methods
Sequence analysis
Sequences belonging to Dexras/Rhes protein group were obtained by BLAST searches on Swissprot, TREMBL, and TREMBLNEW databases (Bairoch and Apweiler, 2000) using Rhes1 sequence from Rat (EMBL Accession number: Q9WVD3). Ras-related sequences in Swissprot belonging to main subfamilies (Ras, Rho, and Rab) were exhaustively collected using ISS-BLAST (Intermediate Sequence Searches) (Park et al., 1997) . Multiple sequences alignment were built with CLUSTALW using BLOSUM62 matrix (Henikoff and Henikoff, 1992) for Rhes and the other Ras sequence subfamilies. Phylogenetic classification of Rhes sequences into the whole Ras sequences were carried out with CLUSTALW using gene tree bootstrapping calculation method (Thompson et al., 1994) .
Cell cultures
NIH 3T3 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% calf serum. COS-7 and HeLa cells were grown in the same medium. The rat pheochromocytoma cell line, PC12, was cultured in DMEM supplemented with 5% foetal calf serum (FCS) and 10% horse serum (HS). For focus forming assays, 1.5 Â 10 5 NIH3T3 cells were plated the day before transfection onto a 100 mm culture dish. DNA transfection was performed using Lipofectamine Plus reagent (Life Technologies, Rockville, MD, USA), as recommended by the manufacturer. After transfection, the medium was changed twice a week, and the number and quality of foci were scored every week. The plates were fixed in 100% cold methanol and stained with 10% Giemsa (Merk) in phosphatebuffered saline (PBS). Other cells used for studies of Rhes expression included N2a neuroblastoma cells (Americal Type Cell Culture Collection, CCL 131), hypothalamic GT1-7 cells (Mellon et al., 1990) , C6 glioma cells, and 'P' cells, immortalized neurons from E18 embryonic rat brain (Mun˜oz et al., 1993) .
CAT activity assays
Cells were transfected with CAT reporter constructs using Lipofectamine. As an internal control for transfection efficiency, we used the plasmid pCH110 (Pharmacia LKB) encoding b-galactosidase under control of SV-40 early promoter. At 36 h after transfection, the cell extracts were incubated with 25 nCi of [ 14 C]chloramphenicol and 800 mM acetyl-CoA, in a final volume of 100 ml of 0.25 M Tris HCl, pH 7.5 at 371C for 2 h. The reaction products were extracted with 550 ml of ethyl acetate and fractionated by thin-layer chromatography on silicagel plates followed by autoradiography. Quantifications were performed after exposure of the plates in an Instant Imager electronic detector (Packard).
GTP/GDP binding assay
Cells were transfected with 1 mg each of H-RasV12, Rhes and H-Ras, in the PCEFL expression vector containing the AU5 epitope for immunoprecipitation. The cells were kept for 48 h in DMEM supplemented with 10% FCS, and then incubated overnight with phosphate-free DMEM (Sigma-Aldrich, St Louis, MO, USA). The cells were incubated with 0.05 mCi/ml of 32 P-orthophosphate for 6 h, and the GTP-binding protein was immunoprecipitated with anti-AU5 antibody at a final 1 : 500 dilution (BabCo) and incubated with 20 ml of g-bind G-Sepharose (Pharmacia) for 15 min on ice. The immunoprecipitates were washed three times with cold buffer (50 mM TrisHCl, pH 7.5, 20 mM MgCl 2 , 500 mM NaCl, 0.5% Nonidet P-40), and the bound nucleotides were released by heating at 681C for 2 min. Eluted nucleotides were analysed by PEI cellulose thin-layer chromatography (Merck) and the proportion of GTP-bound over total GTP þ GDP was calculated. The data from different experiments were pooled to calculate statistical significance by ANOVA. The calculations were performed using the SPSS statistical package (SPSS Inc., Chicago, IL, USA).
Intracellular localization
PC12 cells were plated at low density on poly-L-lysine-coated coverslips. They were then transfected with either GFPexpression vectors containing the constructs of interest, or pCEFL expression vectors containing the AU5 epitope, using Lipofectamine in serum-free medium (Optimem 1, Gibco BRL) for 5 h. After washing, the cells were maintained in growth medium for 24 h. Cells were rinsed in PBS, fixed in 3.7% formaldehyde for 15 min, washed with PBS, and mounted in Mowiol for direct fluorescence of GFP. For indirect immunofluorescence, the cells were fixed in 4% paraformaldehyde, washed with 0.1 M glycine in PBS for 15 min and then permeabilized with 0.5% Triton X-100 in 0.1 M glycine in PBS for 15 min and blocked with 3% BSA in PBS for 30 min. Incubation with the mouse anti-AU5 antibody at a 1 : 100 dilution (BAbCo) was for 1 h at room temperature. After rinsing three times with PBS, the cells were stained with FITC-conjugated goat anti-mouse IgG (Jackson Immuno Research Laboratories, 1 : 100 dilution) at room temperature in the dark. After washing, the coverslips were mounted with Mowiol and viewed in a confocal microscope. The effect of farnesylation or geranylgeranylation inhibitors was assessed by treatment of the cells with FTI-277 or GGTI-298 (Calbiochem), respectively, as described (Lerner et al., 1995a, b) .
In vitro binding assays
The Raf(amino acids 1-149) and p110 subunit of PI3K (amino acids 127-314) RBDs, in the expression vector pGEX, were prepared from 400 ml of overnight Escherichia coli culture and coupled to 300 ml of glutathione-agarose beads (PharmaciaBiotech). HeLa cells were transfected with expression vectors encoding Ras proteins, and 400 ml of cell lysate (lysis buffer was 25 mM HEPES pH 7.3, 150 mM NaCl, 10 mM MgCl 2 10, 0.5 mM EGTA, 0.5% Triton X-100, 4% glycerol, 100 mg/ml PMSF, 10 mM NaF, 20 mM b-glycerol phosphate, 10 mM Na 3 VO 4 , and 2 mg/ml each of leupeptin and aprotinin) was incubated with 30 mg of GST fusion proteins for 3 h at 41C in a rotating wheel. After pelleting the beads, the proteins were solubilized and immunoblotted using the anti-AU5 antibody.
Kinase activity assays
To evaluate the effect of Rhes on the MAP kinase pathway, approximately 1 Â 10 6 COS-7 cells were transfected by standard calcium phosphate precipitation with 1.0 mg of an HA-tagged MAPK/Erk2 expression plasmid together with either 3 mg of wild-type Rhes, 3 mg of H-Ras, 1 mg of H-Ras V12, or 3 mg of H-Ras N17 in the expression plasmid pCEFL. At 48 h after transfection, the cells were starved in serumfree medium for 16 h and subsequently lysed in 400 ml of 20 mM HEPES (pH 7.5), 10 mM EGTA, 40 mM b-glycerol phosphate, 1% NP-40, 2.5 mM MgCl 2 , 2 mM Na 3 VO 4, 1 mM DTT, 100 mg/ml PMSF, 2 mg/ml leupeptin, 2 mg/ml aprotinin. Exogenously expressed Erk2 was immunoprecipitated from the total cell lysate using an anti-HA antibody for 1 h at 41C, followed by coupling 15 ml of g-bind G-Sepharose (Pharmacia) for 20 min at 41C. Immune complexes were washed three times with 1% NP-40 and 2 mM Na 3 VO 4 in PBS, followed by one wash in 5 mM LiCl, 100 mM Tris (pH 7.5), and one wash in kinase reaction buffer (12.5 mM b-glycerol phosphate, 7.5 mM MgCl 2 , 0.5 mM EGTA, 0.5 mM NaF, 0.5 mM Na 3 VO 4 , 1 mM DTT, 12.5 mM MOPS pH 7.5). Kinase activity assay was performed in 30 ml of reaction buffer, containing 1.0 mCi of [g 32 P]ATP, 20 mM unlabelled ATP, 1 mM DTT, and 40 mg of myelin basic protein (Sigma, MO, USA), and incubated at 301C for 30 min. Aliquots (30 ml) of the reaction mixture were subjected to 14% acrylamide SDS gel electrophoresis.
To evaluate the effect of Rhes on the PI3 kinase pathway, 3.0 mg of expression plasmid was cotransfected with 1.0 mg of HA-Akt expression plasmid in COS-7 cells. Approximately 48 h after transfection, cells were starved in serum-depleted medium for 16 h and subsequent cell lysis and kinase reaction were performed. For Akt protein kinase activity assay, cells were lysed in NP-40 lysis buffer (1% NP-40, 10% glycerol, 150 mM NaCl, 20 mM Tris pH 7.4, containing 2 mg/ml aprotinin, 2 mg/ml leupeptin, 100 mg/ml PMSF, 20 mM NaF and 1 mM Na 3 VO 4 ). Immunoprecipitation was carried out for 2 h at 41C with rotation, using an anti-HA antibody followed by coupling 20 ml of g-bind G-Sepharose (Pharmacia) for 1 h at 41C with rotation. The immunoprecipitates were washed three times with lysis buffer, once with water, and once with the Akt kinase buffer (20 mM HEPES, pH 7.4, 10 mM MgCl 2 , 10 mM MnCl 2 . Kinase assay was performed in 30 ml of Akt kinase buffer, containing 3 mCi of g 32 P-ATP, 20 M unlabelled ATP, and 3 mg of histone H2B), and incubated at 301C for 30 min. Equal aliquots (30 ml) of the reaction mixture were subjected to 16% polyacrylamide-SDS gel electrophoresis.
In situ hybridization
In situ hybridization was performed as described previously (Vargiu et al., 2001) . Briefly, 25 mm thick coronal and saggital slices were obtained in a cryostat from paraformaldehyde-fixed adult rat brains. The slices were hybridized using a free floating technique with a Rhes riboprobe synthesized from nucleotides 1431-1869 of Rhes cDNA in the presence of [ 35 S]UTP. After hybridization and further processing of the slices as described, the slices were mounted on glass slides for autoradiography.
Activation of the cAMP pathway
The cAMP pathway was activated in PC12 cells by transfection with expression vectors encoding a constitutively activated b2-adrenergic receptor (Samama et al., 1993) , the activated Gas mutant, GasQL (Landis et al., 1989; Crespo et al., 1995; Vargiu et al., 2001) , or by 10 mM forskolin. In another experiment, the cells were stimulated with bovine TSH (Sigma-Aldrich Co., St Louis, MO, USA) after transfection with the human TSH receptor (kindly supplied by Dr Gilbert Vassart, Free University of Brussels, Belgium). The cells were cotransfected with a CAT reporter under control of a tandem repeat of four cAMP responsive elements (CRE) and CAT assays were performed as described above.
